Table 2. Hazard ratio (HR) and 95% confidence intervals (CI) for cancer types between agricultural workers by gender.
| Sites/Types | Male | Female | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Model 1 a | Model 2 b | Model 1 a | Model 2 b, c | |||||||||||
| Cases | HR | 95% CI | HR | 95% CI | Cases | HR | 95% CI | HR | 95% CI | |||||
| Overall Cancer | 90 678 | 1.10 | 1.09‒1.11 | 1.11 | 1.10‒1.13 | 46 235 | 0.97 | 0.96‒0.98 | 0.97 | 0.95‒0.99 | ||||
| Malignant neoplasm of lymphatic and haemopoietic tissue | ||||||||||||||
| Lymphocytic leukemia | 1652 | 1.11 | 1.04‒1.19 | 1.12 | 1.04‒1.21 | 732 | 1.06 | 0.95‒1.17 | 1.07 | 0.96‒1.19 | ||||
| Acute myelogenous leukemia (AML) | 633 | 1.10 | 0.99‒1.23 | 1.07 | 0.95‒1.20 | 305 | 1.14 | 0.96‒1.34 | 1.14 | 0.96‒1.35 | ||||
| Acute lymphoblastic leukemia (ALL) | 45 | 1.36 | 0.87‒2.13 | 1.31 | 0.83‒2.07 | 14 | 0.50 | 0.26‒0.95 | 0.50 | 0.26‒0.95 | ||||
| Chronic myelogenous leukemia (CML) | 223 | 1.24 | 1.02‒1.51 | 1.26 | 1.03‒1.55 | 79 | 0.94 | 0.69‒1.27 | 0.97 | 0.71‒1.33 | ||||
| Chronic myelogenous leukemia (CLL) | 169 | 0.97 | 0.78‒1.20 | 1.07 | 0.85‒1.34 | 63 | 0.92 | 0.65‒1.30 | 0.90 | 0.64‒1.29 | ||||
| Other leukemia | 582 | 1.11 | 0.98‒1.25 | 1.13 | 0.99‒1.28 | 271 | 1.12 | 0.94‒1.33 | 1.13 | 0.95‒1.35 | ||||
| Lymphoma | 2578 | 1.06 | 1.00‒1.12 | 1.08 | 0.99‒1.17 | 1340 | 1.09 | 1.00‒1.17 | 1.11 | 0.99‒1.24 | ||||
| Hodgkin’s lymphoma | 76 | 0.78 | 0.58‒1.05 | 0.62 | 0.39‒0.98 | 42 | 1.35 | 0.85‒2.14 | 2.11 | 0.95‒4.66 | ||||
| Non-Hodgkin’s lymphoma (NHL) | 2502 | 1.07 | 1.01‒1.13 | 1.10 | 1.01‒1.20 | 1298 | 1.08 | 1.00‒1.17 | 1.09 | 0.98‒1.22 | ||||
| B-cell lymphomas | 1503 | 1.04 | 0.97‒1.12 | 1.09 | 0.99‒1.21 | 841 | 1.09 | 0.99‒1.21 | 1.07 | 0.93‒1.22 | ||||
| Natural killer (NK)/T-cell lymphoma | 275 | 1.06 | 0.89‒1.25 | 0.99 | 0.76‒1.28 | 102 | 0.92 | 0.71‒1.21 | 0.94 | 0.63‒1.40 | ||||
| Other lymphoid | 724 | 1.15 | 1.03‒1.28 | 1.18 | 0.99‒1.39 | 355 | 1.10 | 0.94‒1.27 | 1.23 | 0.99‒1.53 | ||||
| Multiple myeloma | 555 | 1.17 | 1.04‒1.33 | 1.16 | 0.97‒1.39 | 283 | 1.19 | 1.00‒1.41 | 1.29 | 1.02‒1.63 | ||||
| Malignant neoplasm of lip, oral cavity and pharynx | ||||||||||||||
| Oral | 7688 | 1.23 | 1.19‒1.27 | 1.29 | 1.23‒1.35 | 506 | 0.92 | 0.82‒1.04 | 0.93 | 0.78‒1.10 | ||||
| Lip | 432 | 1.38 | 1.20‒1.60 | 1.55 | 1.27‒1.89 | 49 | 1.11 | 0.74‒1.66 | 1.13 | 0.64‒1.98 | ||||
| Larynx | 1066 | 1.01 | 0.93‒1.10 | 1.11 | 0.98‒1.26 | 24 | 0.61 | 0.37‒1.02 | 0.59 | 0.27‒1.28 | ||||
| Major salivary glands | 215 | 1.02 | 0.84‒1.23 | 0.94 | 0.71‒1.25 | 99 | 0.89 | 0.68‒1.17 | 0.78 | 0.53‒1.15 | ||||
| Malignant neoplasm of digestive organs and peritoneum | ||||||||||||||
| Esophagus | 3645 | 1.18 | 1.13‒1.24 | 1.29 | 1.21‒1.38 | 145 | 0.79 | 0.63‒0.98 | 0.79 | 0.58‒1.07 | ||||
| Stomach | 4462 | 1.03 | 0.99‒1.07 | 1.08 | 1.01‒1.15 | 1653 | 1.03 | 0.96‒1.11 | 0.97 | 0.88‒1.08 | ||||
| Colon (excluding rectum) | 7607 | 0.96 | 0.93‒0.99 | 0.95 | 0.91‒0.99 | 3942 | 0.96 | 0.92‒1.01 | 0.98 | 0.92‒1.04 | ||||
| Rectum and rectosigmoid junction | 5840 | 1.14 | 1.10‒1.18 | 1.12 | 1.06‒1.18 | 2357 | 1.04 | 0.98‒1.10 | 1.03 | 0.95‒1.12 | ||||
| Sigmoid colon | 3498 | 1.01 | 0.96‒1.06 | 0.98 | 0.92‒1.05 | 1486 | 0.94 | 0.88‒1.01 | 0.96 | 0.87‒1.05 | ||||
| Anus, anal canal, and anorectum | 52 | 0.53 | 0.38‒0.74 | 0.70 | 0.42‒1.16 | 40 | 0.74 | 0.49‒1.11 | 0.75 | 0.43‒1.32 | ||||
| Liver and intrahepatic bile duct | 15 480 | 1.17 | 1.15‒1.20 | 1.19 | 1.15‒1.23 | 4186 | 0.97 | 0.93‒1.01 | 1.00 | 0.95‒1.07 | ||||
| Malignant neoplasm of respiratory and intrathoracic organs | ||||||||||||||
| Lung | 13 210 | 1.15 | 1.12‒1.18 | 1.17 | 1.13‒1.22 | 4582 | 0.96 | 0.92‒1.00 | 0.98 | 0.93‒1.04 | ||||
| Trachea and bronchi | 306 | 1.26 | 1.06‒1.49 | 1.36 | 1.00‒1.86 | 42 | 0.77 | 0.52‒1.16 | 0.63 | 0.31‒1.30 | ||||
| Malignant neoplasm of bone, connective tissue, skin and breast | ||||||||||||||
| Bones, joints, and articular cartilage | 78 | 1.12 | 0.81‒1.54 | 1.34 | 0.81‒2.21 | 43 | 1.07 | 0.70‒1.65 | 1.25 | 0.65‒2.41 | ||||
| Connective, subcutaneous and other soft tissues | 373 | 0.91 | 0.79‒1.05 | 0.87 | 0.70‒1.07 | 218 | 1.12 | 0.93‒1.36 | 1.21 | 0.91‒1.60 | ||||
| Melanoma of skin | 137 | 1.20 | 0.94‒1.54 | 1.14 | 0.79‒1.66 | 86 | 1.82 | 1.27‒2.60 | 1.71 | 1.00‒2.93 | ||||
| Other non-melanoma skin | 3269 | 1.20 | 1.14‒1.26 | 1.22 | 1.14‒1.31 | 1772 | 1.19 | 1.11‒1.27 | 1.20 | 1.09‒1.32 | ||||
| Female breast | 9443 | 0.86 | 0.84‒0.88 | 0.84 | 0.81‒0.88 | |||||||||
| Malignant neoplasm of genital organs | ||||||||||||||
| Uterus, not otherwise specified | 5339 | 0.10 | 0.01‒0.78 | 0.51 | 0.05‒5.57 | |||||||||
| Ovary, fallopian tube, and broad ligament | 984 | 0.86 | 0.79‒0.94 | 0.88 | 0.78‒1.00 | |||||||||
| Prostate gland | 8005 | 1.01 | 0.98‒1.05 | 1.00 | 0.96‒1.05 | |||||||||
| Malignant neoplasms of urinary tract | ||||||||||||||
| Bladder | 3210 | 1.01 | 0.96‒1.06 | 1.04 | 0.97‒1.12 | 843 | 1.01 | 0.92‒1.11 | 1.01 | 0.89‒1.16 | ||||
| Kidney | 811 | 0.78 | 0.72‒0.86 | 0.73 | 0.64‒0.83 | 343 | 0.99 | 0.85‒1.15 | 1.18 | 0.95‒1.45 | ||||
| Malignant neoplasm of nervous system | ||||||||||||||
| Brain | 568 | 1.09 | 0.97‒1.22 | 0.98 | 0.82‒1.18 | 286 | 1.06 | 0.90‒1.25 | 1.11 | 0.88‒1.40 | ||||
| Thyroid gland | 580 | 0.91 | 0.81‒1.01 | 0.80 | 0.68‒0.93 | 1689 | 1.03 | 0.96‒1.10 | 0.98 | 0.90‒1.08 | ||||
a The follow-up time period spanned from the initial insurance date (1 January 2000) until either the date of cancer diagnosis or the study end date (31 December 2018). b In Model 2, we excluded participants who had been newly diagnosed with solid tumors and had not been insured for >10 years, as well as participants who had been newly diagnosed with hematological tumors and had not been insured for ≥2 years. For solid tumors, the follow-up time period was defined as starting from the date of 10 years of insurance coverage and continuing until either the date of cancer diagnosis or the study end date (31 December 2018). For hematological tumors, the follow-up time period was defined as starting from the date of 2 years of insurance coverage and continuing until either the date of cancer diagnosis or the study end date (31 December 2018).